Aurinia Pharmaceuticals Inc (AUPH)

[northern vortex]

IMHO – it appears that the primary concern of the FDA is for the Ph III trial to demonstrate a meaningful functional improvement in the lives of patients known to have LN, rather than as the SA article suggests - a need to meet of some histological milestone or “cure” as shown through a biopsy.